– New safety and feasibility data from Phase 1/1b PERIO-03 trial for locally advanced pancreatic cancer supports further development of the novel TriSalus Infusion System for therapeutic delivery via ...
WESTMINSTER, Colo., November 18, 2025--(BUSINESS WIRE)--TriSalus Life Sciences, an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for ...
DENVER--(BUSINESS WIRE)--TriSalus TM Life Sciences (“TriSalus”), a company committed to transforming outcomes for patients with solid tumors, today announced the launch of its TriNav™ Infusion System ...
– Data published in Current Medical Research and Opinion provide a comparison of the TriNav Infusion System vs. standard drug delivery and show the ability of TriNav to successfully treat sicker, ...
Improved Tumor Penetration: PEDD achieved a 227 % increase (p=0.029) in the concentration of fluorescently labeled Embospheres within tumor tissue compared to a traditional microcatheter. Improved ...
Pressure enabled drug deliver (PEDD) method significantly increased penetration of glass microspheres into porcine liver tumors (117%; p=0.004 and 39%; p=0.032) with lobar infusions and selective ...
DENVER--(BUSINESS WIRE)-- TriSalus Life Sciences (TLSI) ®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), TriSalus Life Sciences seeks to transform outcomes for patients with solid tumors by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results